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Sllmmal'y 
BALB/c mice (H-2  d, Mls-1 b) from one colony progressively modify their T cell repertoire during 
aging, by deleting T cells that express products of the V~6 and V~8.1 genes of the T cell receptor. 
Clonal deletion occurs only in 50%  of mice between 27 and 43 wk of age,  affecting thymus, 
spleen, and lymph node T  cells. The phenomenon is progressive and seems to affect nearly all 
thymuses between 14 and  19 wk of age.  CD4+CD8 -  mature T  cells are more affected than 
CD4-CD8 + cells. In the thymus, deletion occurs at the stage of immature Jlld + cells expressing 
a high  level of V~6,  while J11d +  VB61~  cells  are not modified.  Clonal  deletion is 
thus an early phenomenon that deletes cells of the immature generative compartment in the thymus. 
This  Mls-l~-like clonal deletion  is associated neither  with  the expression  of an Mls-P-like 
antigen that could be identified in mixed lymphocyte reaction in vitro,  nor with the presence 
of Mtv-7,  the endogenous mouse mammary tumor virus (MMTV) proviral loci.  Spleen cells, 
bone marrow cells, and total thymocytes injected into newborn thymuses cannot induce VB6 + 
cell deletion. However, newborn thymuses grafted into old ItALB/c mice behave like their recipients, 
suggesting that a new antigen,  present in these old BALB/c  mice, is indeed able to induce an 
Mls-l~-like  clonal deletion.  As other BALB/c colonies tested do not behave in the same way, 
the hypothesis of a new exogenous deleting factor rather than a genetic transmission  is likely. 
This may suggest that acquired clonal deletion is a more common phenomenon than expected, 
and may be the spontaneous reaction of the immune system to the introduction of a new retrovirns 
or other  superantigen. 
C 
lonal deletion during intrathymic  T  cell development 
is one of the mechanisms  that  induces self-tolerance. 
This mechanism has been well described in mice expressing 
the minor lymphocyte-stimulating (Mls) gene products (1). 
Mls products were initially defined by a capacity to induce 
a strong proliferative response in mixed lymphocyte culture 
between cells from H-2-compatible strains  (2).  Cells reac- 
tive  to  Mls-1 ~ that  specifically  use  the  products  of V~6, 
V/~8.1,  and VB9 genes of the TCR were absent or highly 
reduced in mature  T  cells of Mls-1 a mice (3-5).  Until  re- 
cently, the nature of the Mls antigens able to stimulate specific 
T cells or to induce tolerance was not known. Frankel et al. 
(6) have shown that Mls-1 ~ antigen is the product of an en- 
dogenous mouse mammary tumor virus (MMTV) 1 proviral 
loci, the Mtv-7 located on chromosome one. Strikingly, prod- 
ucts of other endogenous or exogenous MMTV were shown 
to control the deletion of other specific T cell subsets (7-11). 
Based on studies involving a large number of mouse strains, 
the conclusion is that  the Mls-1 a phenotype, including de- 
letion of V~6 and VB8.1 T  cells,  is always associated with 
1Abbreviation used in this paler: MMTV, mouse mammary tumor virus. 
the presence of the same Mtv-7 provirus (6), and conversely, 
that none of the Mls-1 b strains is Mtv-7 positive (3, 4, 10). 
In the present report we described an exception to this rule 
showing  that  BALB/c,  Mls-1 b mice from one colony pro- 
gressively modify their T cell repertoire in an Mls-P fashion 
by deleting  VB6 and VBS.1 T  cells. 
Materials and Methods 
Mice.  The following mice were used at different ages (8 d to 
43  wk):  BALB/c (H-2 d,  I-E +,  Mls-lb),  DBA/2  (H-2 d,  I.E.*, 
Mls.P), and C57BL/6 (H-2  b, I-E-, Mls-1  b) were purchased from 
Iffa-Credo (L 'Arbresle,  France); CBA/Ca (H-2 k,  I-E +,  Mls-1  b) 
were bred in our own facilities. BALB.D2 mice (H-2 d, I-E +, Mls- 
P) (13) were a gift of L. Berumen, Institut Nationale de la Sant6 
et de la Recherche Mtdicale (INSERM U 267). Mice of the 13th 
backeross generation were used to generate a homozygous BALB.D2 
congenic strain. BALB.D2, which are identical to BALB/c for H-2 
expression, are maintained in a strict congenic state. B10BR (H- 
2  k, I-E +, Mls-lb), B10.D2 (H-2 d, I-E +, Mls-1  b) C3H/Hej (H-2  k, 
I-E +  , Mls-1  b) SJL/J (H-2  ~, I-E-, Mls'l b) and A/J (H-2 k/d, I-E +  , 
Mls-1  b) were purchased from Centre de selection et d'61evage des 
animaux de laboratoire (CSEAL) (Orltans, France). Mice from Iffa- 
Credo (BALB/c and C57BL/6) were issued from The Jackson Lab- 
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formity. 
All results presented in figures  and tables  are those of experi- 
ments performed with female mice, but the same results were ob- 
tained with males. 
Antibodies.  The following mAbs were used: anti-CD4 (rat IgG, 
clone GK 1-5, and rat IgM, clone RL 172.4) (14, 15); anti-CD8 
(rat IgG, clone 53-6.7, and rat IgM, clone 3-155) (16, 17); anti-V38 
antibodies (clone KJ16-D3, clone F23-2) (18, 19); (KJ 16-133 recog- 
nizing the product of VB 8.1 and V3 8.2; F23-2 recognizing the 
product of V3 8.2; anti-V36 (clone 44-22.1) (20); anti-HSA (clone 
Jlld)  (21). 
CellPreparation.  Thymus, spleen, and peripheral lymph nodes 
(inguinal and axillary) were removed under sterile conditions. Cells 
were isolated and filtered. To isolate mature CD4 + and CD8 + cells 
from the thymus, total thymocytes were incubated with either 
anti-CD8 or anti-CD4 rat IgG antibodies for 30 rain at 4~  and 
then treated for another 30 min with magnetic beads coated with 
anti-rat lgG (Dynabeads; Dynal, Oslo, Norway). Positive cells were 
then removed with a magnet. For mixed lymphocyte cultures, spleen 
cells were depleted of CD4 + and CD8 + cells by treatment with 
anti-CD8  and anti-CD4 IgM rat antibodies and C'. 
lmmunofluorescence.  Freshly isolated  cells were double labeled 
with FITC-labeled anti-CD4 or anti-CD8, or Jlld, and biotinylated 
anti-V/~ antibodies which were revealed by streptavidin-PE  (Caltag 
Laboratories, San Francisco, CA). Flow microfluorometric analysis 
was performed using a FACScan  |  flow cytometer (Becton Dick- 
inson and Co., Mountain View, CA). The percentage of V/~8.1 
cells was  defined by subtracting the percentage of F23.2 + cells 
from that of KJ16 + ceils. 
Thymus Grafting.  Newborn BALB/c thymuses were removed 
under sterile  conditions within 24 h  of birth and grafted under 
the kidney capsule  of 36-wk-old BALB/c mice.  5 wk later,  the 
recipients' thymus grafts, thymus, and lymph nodes were removed. 
CD4 § mature thymocytes were isolated as described above. Thy- 
mus and lymph node lymphocytes were then labeled with anti-CD4 
and anti-V~6  antibodies. 
Mixed Lymphocyte Cultures.  Stimulator spleen cells were pre- 
pared from 6- and 36-wk-old BALB/c and from 8-wk-old BALB.D2- 
Mls-P according to the protocol of Webb et al. (22). Spleen cells 
were enriched in  CD8-CD4-  cells (acknowledged  as the best 
stimulators  for  Mls  reaction),  by  using  both  anti-CD4  and 
anti-CD8 IgM antibodies and complement. Stimulator spleen cells 
were irradiated at 2,000 rad. Responder 6-wk-old thymocytes were 
enriched in CD4 § cells by treatment with anti-CD8 IgM anti- 
body and C'. 5  x  l0  s thymocytes and 5  x  105 irradiated spleen 
cells were cultured in 200/zl RPMI 1640 medium containing 1% 
Na Pyruvate, penicillin, and streptomycin, 10% FCS and 10 -s M 
5-ME (Gibco Laboratories, Grand Island, NY). Cells were cultured 
for 4 d at 37"C in a 5% CO2 humidified atmosphere and were 
pulsed for the last 4 h with 1/zCi (37 kBq) of [3H]thymidine (sp 
act 1 Ci/mmol). Cells of clone F5J10 (23) (gift ofM. Bruley-R_osset, 
INSERM U267,  Villejuif,  France)  (a V/36 + Mls-l' reactive cell 
line),  were also used as responder cells, however,  2  x  104 cells 
were used per well. 
In  Vivo Tolerance Induction.  BALB/c mice were injected in- 
traperitoneally  within 24 h of birth with 10  a total spleen cells after 
red blood cell lysis or with 25  x  l& bone marrow cells. Old 
BALB/c spleen cells were tested before injection for V~6 expres- 
sion within the CD4 + mature T cell population. Spleen cells de- 
rived from mice that had deleted VB6 were used for injection. 
BALKD2-Mls-P spleen and bone marrow cells were also injected. 
Injected newborn mice were tested 5-8 d, 11 d, or 4-5 wk later 
for the expression of V~6 within  the CD4*CD8 -  thymocyte 
population after depletion of CD8 + cells as aforementioned. 
Genomic DNA Analysis.  High molecular weight DNA was ex- 
tracted from frozen spleens. DNAs (10/~g) were digested with Pvull 
or EcoRI restriction enzymes under reaction conditions recom- 
mended  by  the  manufacturers.  Hybridization with  3zp-labeled 
MMTV long terminal repeat (LTR) probe (24) was done according 
to standard procedures (25). Spleen of DBA/2 (MIs.P), BALB.D2- 
Mls.P,  and VB6-deleted or normal BALB/c were analyzed. 
Results 
Age-related,  Mls-1"-like  Deletion  in  Mature  T  Cells  of 
BALB/c, MIs-I b Mice.  We analyzed the chronological V/~ 
expression of mature T cells from the thymuses, lymph nodes, 
and  spleens of BALB/c mice.  Fig.  1  shows the percent of 
V/~6 + CD4+CD8 -  mature thymocytes in BALB/c, Mls-1 b 
mice. The percentage of V/~6 + CD4 + CD8-  mature thymo- 
cytes from BALB.D2-Mls-I' mice served as a comparison for 
Mls-1 ~ deletion.  1-2-wk-old BALB/c mice had the highest 
percentage of V/~6 +  cells in  the thymus  (up  to  18%).  In 
young adult 5-8-wk-old BALB/c, the percentage of V/~6 + 
cells ranges from 6 to 13% in the thymus and 5 to 13.5% 
in the lymph nodes. Between 27 and 43 wk of age, ,v50% 
of BALB/c mice have deleted VB6 + cells similar to the level 
of BALB.D2-Mls-P  mice.  V~6 +  cells  were always  simul- 
taneously deleted in the thymus, spleen, and lymph nodes. 
During the intermediary period between  14 and  19 wk of 
age,  the  situation  became  more  complex.  The  range  of 
V/~6 + cells was lower in CD4 + CD8-  thymocytes (between 
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Figure 1.  Chronological expression of V/~6  + CD4 + CD8- T cells in 
the thymus, spleen, and lymph nodes of BALD/c, Mls-1  b mice. Vfl6 ex- 
pression was determined by double immunofluorescence  staining using 
anti-CD4-FITC and biotinylated  anti-V/% (clone  44-22.1). The percentage 
of V/36* T cells is expressed  within CD4+CD8 - mature T cells, in the 
thymus CD4* CDS- T ceils were purified using anti-CD8 and anti-rat 
antibody-coated magnetic beads. BALB.D2 CD4+CD8 -  thymocytes 
were used as a control for Mls-1, phenotype. 
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lymph nodes, two distinct groups of mice were already evi- 
dent.  One  group  had  a  high  level  of  V~6  expression 
(10.2-13%) and the other had a low level of V~6 (1.5-4%). 
The mice with the lowest percentage of V~6 § thymocytes 
also had the lowest percentage of VB6 + cells in the lymph 
node. These results suggested that  14-19owk-old mice un- 
dergo a "crisis" that affects most, if not all,  thymuses and 
leads to partial or total deletion of Vfl6 + cells. Subsequently, 
some of the mice then appear to recover from this crisis and 
contain normal levels of V~6 + cells in the thymus, spleen, 
and lymph nodes between 27 and 43 wk of age. 
As  for Mls-1 a mice,  deletion of Vfl6 in  BALB/c aging 
mice is associated with VB 8.1 deletion, and expression of 
Vfl 8.2 is not modified (Table 1). Expression ofV~6, VB 8.1, 
and VB  8.2  was  also  tested in  seven  other Mls-1 b strains 
(with or without I-E expression) between 27 and 43 wk of 
age (CBA/Ca, B10 BR, C57BL/6, C3H/HeJ, A/J, SJL/J, 
and B10D2). None of them showed an Mls-P-like ddetion 
during  aging.  VB14 + ceils that  are deleted by exogenous 
MMTV in C3H/HeJ mice (9) were not ddeted in BALB/c- 
deleting Vfl6 + cells  (data not shown). 
V~6 Deletion in Thymocyte Subpopulations of  Aging BALB/c 
Mice.  J11d  labeling  was  used  to  discriminate  immature 
(Jlld +) from mature (Jlld-) thymocytes (Table 2). In 5-8- 
wk-old mice, 8.6% Jlld-  thymocytes, which contain ma- 
ture  thymocytes,  expressed  high  levels  of V~6.  Within 
immature Jlld +,  two  subpopulations could be identified, 
expressing low or high levels of VB6 (V/36  l~  and v~6high). 
In aging mice, those that delete V/~6hig  h Jlld-, mature T 
ceils also delete the small fraction of Jlld + V~6his  h imma- 
ture thymocytes. The percentage ofJlld § VB6  l~  immature 
calls was the same in 5-8-wk-old and normal, or modified 
27-43-wk-old mice. Fig.  2  shows  that when Jlld-  V/36 + 
Table  1.  Repertoire of Thymus  and Lymph Node BALB/c  CD4+CD8 -  and CD4-CD8 + T  Cells as a Function of Age 
Mice with nondeleted VB6  Mice with deleted VB6 
Subpopulation 
tested  Age  V~6  V/3  8.1  Vfl 8.2  VB6  VB  8.1  V/3 8.2 
wk 
Thymus  CD4 § CD8-  5-8 
Thymus  CD4 +  CD8-  27-45 
Thymus  CD4-CD8 §  27-45 
Lymph nodes CD4+CD8 -  5-8 
Lymph nodes CD4 +  CD8-  27-45 
Lymph nodes CD4-CD8 §  27-45 
9.5  _+  0.4  4.3  _+  0.4  11.9  +  0.4  No VB6-deleted mice 
10.2  +  0.4  5.9  _+  0.9  18.0  +_  0.9  1.6  _+  0.2  2.9  +  0.5  19.9  _+ 0.8 
8.2  _+  0.8  8.0  +  1.0  12.5  _+  1.5  3.1  _+  0.3  NT  16.3  _+  0.7 
10.2  _+  0.6  5.6  +  0.2  12.4  _+  0.3  No V~6-deleted mice 
11.1  _+ 0.2  7.0  _+  0.3  12.1  +_ 0.3  1.2  _+  0.2  1.8  +  0.6  15.8  _+ 0.9 
12.2  +  0.3  9.7  _+  0.2  17.9  _+  0.5  4.4  +  0.3  5.5  +  0.4  22.2  _+  1.0 
CD4+CD8 -  and CD4-CD8 + thymic cells are isolated by negative selection using anti-CD8 or anti-CD4 antibodies  and anti-rat Ig-coated beads. 
Thymus or lymph node T cells are double labeled with anti-CD4 or anti-CD8 FITC and biotinylated Vfl6 revealed by streptavidin  PE. Expression 
of Vfl6 Vfl 8.1  and Vfl 8.2 is given within a group of mice who have or have not deleted their V~6 in CD4 + T cells as shown in Fig. 1. Results 
are expressed  as the percentage  of VB + cells (mean  value  •  SEM). 
Table  2.  Chronological  Examination of Vfl6 Expression within Mature JlId-  and Immature JIld + BALB/c  Thymocytes 
Percent  V~6  within 
total Jlld § 
Percent  VB6  Percent  V/~6  high within 




9.6  _+  0.5  7.3  ___  0.3  1.4  _+  0.1  15.3  _+  1.1 
2.4  _+  0.2"  6.2  _+  0.5  0.4  _  0.1  2.5  _+  0.4 
7.0  _+  0.5#  7.0  _+  0.3  1.3  _+  0.1  13.2  _+  1.5 
Thymocytes  were double labeled with Jlld-FITC and biotinylated  anti-Vfl6 antibodies. In 27-45-wk-otd  mice, the percentages of Vfl6 +Jlld + thymo- 
cytes were calculated  separately within mice who have deleted Vfl6 or mice with normal VB6 expression  levels in mature Jlld-  subsets. Results 
are expressed  as the percentage  of positive  cells  _+  SEM. 
* Deleted Vfl6 mice. 
* Normal Vfl6 mice. 
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Figure 2.  Expression of Vj36 and Vf18.2 in the thymus of young and 
old BALB/c mice. Total thymocytes were double labeled with anti-Jlld 
FITC and either biotinylated  anti-Vfl6 or anti-VB8.2 (clone F.23.2). The 
absence of V136  §  cells in  the J11d-  mature  thymocyte subset  of old 
BALB/c is associated with deletion of the small subset ofJlld + V/J6hig  h 
cells, while the immature Jlld + V1361~  cells and the Vf18.2  + 
cells are not modified  (compared with thymocytes  of young BALB/c). 
and Jlld + V~6  high cells were deleted, VB 8.2 § cells were not 
modified compared with a normal young BALB/c mouse. 
Deletion was also compared within mature CD4 §  and 
CD8 + T cell subsets. As shown in Table 1, CD4 + cells were 
more extensively deleted  than  CD8 §  cells  in  the lymph 
nodes, and to a lesser degree in the thymus. 
Mls-la-like Deletion in BALB/c Aging Mice Is Not Associated 
with the Expression of Mls-1*-tike Antigen.  Thymocytes from 
young mice enriched in CD4 +  CDS-  cells (acknowledged 
as the best responders for Mls-P antigen) were stimulated 
in vitro by spleen cells enriched in B cells (known to be the 
best presenting cells for Mls-l' antigen). 6-wk-old BALB/c 
thymocytes responded to BALB.D2.  Mls-P spleen cells, but 
were unable to respond to old BALB/c which had deleted 
their V/36 + T  cells (Table 3). A VB6 +, Mls-P-reactive cell 
line  (done  F5J10)  (23),  was  not  reactive  to  BALB/c 
Vf36-deleted spleen cells. 
The  presence of Mls-l'-like  antigen was  also  tested in 
vivo, in an attempt to induce a V156 clonal deletion by in- 
jecting spleen cells of VB6-deleted BALB/c aging mice into 
newborn BALB/c.  Injection of BALB.D2.MIs-P spleen cells 
was used as a positive control. As shown in Table 4, clonal 
deletion can be induced by the injection of BALB.D2 spleen 
cells, but not by the injection of VB6-deleted BALB/c spleen 
cells. 
Newborn Thymuses Grafted into Old Mice Behave Like Their 
Recipients.for V~6 Expression.  Newborn BALB/c thymuses 
were grafted under the kidney capsule of 36-wk-old unmanipu- 
lated BALB/c recipients.  Host and graft cells cannot be traced 
in that system. We know, however, from previous experi- 
ments using newborn thymus grafts of C57B16/Ka  (Thy- 
1.2) into normal adult C57B16/Ba  (Thy-l.1), that after 5 wk, 
all T cells in the recipient thymus, spleen, and lymph nodes, 
and in the thymus graft, were of host origin (unpublished 
data). In the present experiments, we tested V/36 expression 
by  mature  CD4+CD8 -  cells  in  the  thymus  and  lymph 
nodes of the host and in the grafted thymus 5 wk after grafting 
(Table 5). Newborn thymuses that developed in old mice be- 
haved like their host in their V/36 expression. Vj36 was deleted 
in  the grafted thymus if it  was  deleted in the recipient's 
CD4+CD8 -  cells.  Adult  BALB/c  thymus  and  newborn 
grafts are both colonized by the same bone marrow cells of 
the host.  The  hypothesis was  therefore tested  that  bone 
marrow cells may be modified in aging BALB/c in such a 
Table  3,  Response of CD8-  Young BALB/c  Thymocytes and of Cells of Clone FSJIO (Mls-Ia-Reactive Cell Line) to BALB.D2 
Mls-1  ~ and BALB/c Spleen Cells 
MLR by CD8-  responder  thymocytes  MLR by V36 § 
Stimulator  Percent V~36"  (6-wk-old BALB/c)  Mls-P reactive cell line 
BALB.D2-Mlsl  a  1.7  14,359  60.000 
6-wk BALB/c  12.9  2.298  129 
36-wk BALB/c 
1'  2.2  540  425 
2  2.4  337  1.009 
3  1.9  401  119 
4  2.8  267  833 
No stimulator  -  813  48 
Thymocytes of 6-wk-old BALB/c enriched in CD4+CD8 -  cells by treatment with anti-CD8 and C' (5  ￿  10  s per well) or cells of clone F5 J10, 
Vfl6 +, Mls-l~-reactive (2  x  10  6 cells/well) were cultured for 4 d with 10  s irradiated CD4-CD8-  spleen cells (treated with anti-CD8 and anti-CD4 
plus C'). Stimulators  were BALB.D2-Mls-1  a and syngeneic young or old BALB/c spleen cells. Results  are expressed in cpm for each stimulator type 
of cell. 
* Percent Vfl6 expression of CD4 + stimulator  spleen cells. 
* Four different  mice were tested  individually  (one characteristic  experiment). 
456  Acquired Mls-l"-like  Clonal Deletion in Mls-1  b Mice Table  4.  Assay of the Induction of 1/36  Clonal Deletion  by the Injection of BALB.D2.  MTs-1  a or V36-deleted BALB/c  Spleen or 
Bone Marrow  Cells into Newborn  BALB/c 
Type of cells injected 
Spleen ceils  Bone marrow cells 
Vfl6-deleted  Vfl6-deleted 
Time after injection  None  BALB/c  BALB.D2  BALB/c  BALB.D2 
mean _+ SEM 
5-8 d  17.3  •  0.2  15.9  •  0.4  11.6  •  0.2  NT ~  NT 
11 d  13.06  _+  1.6  10.6  _+ 0.7  6.5  •  0.5  NT  NT 
4-5 wk  8.3  _+ 0.4  6.9  +  0.6  1.6  •  0.3  6.8  •  0.2  3.4  •  0.1 
Newborn BALB/c were injected intraperitoneaUy with 10  s total BALB.D2 or Vfl6 deleted BALB/c spleen cells, or with 20  x  106 bone marrow 
cells. Vfl6 expression was tested  5-8 and 11 d, or 4-5 wk later by CD4+CD8 -  thymocytes  of the recipients. 
" NT, not tested. 
way that they were able to induce Vg/6 deletion in the new- 
born grafted thymuses. As shown in Table 4, this was not 
the case. Tolerance to Mls-1 ~ antigen can be induced by the 
injection of BALB.D2.Mls-1 ~ bone marrow cells but cannot 
be obtained by the injection of bone marrow cells from V/~6- 
deleted aging BALB/c mice. 
Mtv-7 Provirus Is Not Present in BALB/c with  VB6 + Cell 
Deletion.  BALB/c mice were examined for endogenous Mtv 
distribution using EcoRI and PvulI digested DNAs. Whereas 
an expected 2.3-kb PvulI fragment Mtv-7 (26) was observed 
in DBA/2 and BALB.D2 DNAS, no fragment corresponding 
to the Mtv-7 locus was detected in DNA of VB6-deleted 
BALB/c. 
Table  5.  VB6 Expression within  Mature  CD4+CD8 -  Cells in 
Recipient Thymus and Lymph Nodes and Thymus Grafts, 5 wk 
after Grafting Newborn Thymuses into 36-wk-old BALB/c 
V36  in CD4 + lymphocytes 
Recipient  number  1  2  3  4 
% 
Recipient lymph nodes  10.8  11.4  0  0.3 
Recipient thymus  9.2  10.6  1.9  1.4 
Thymus graft  10.6  11.3  3.3  2.2 
Old BALB/c recipients, 36-wk-old, were grafted with newborn thymuses 
under their kidney capsules. 5 wk later, thymus and lymph nodes of the 
recipients and thymus grafts  were  removed.  CD4+CDS-  cells of the 
thymuses were enriched as described in Materials and Methods, and both 
thymocytes  and lymph node cells were  double labeled with anti--CD4 
and anti-Vfl6 antibodies. The percentages of Vfl6+  cells are expressed 
within CD4 § lymph node and thymic cells. Results are given for two 
Vfl6-deleted and two Vfl6 nondeteted  recipients. 
Discussion 
We show in the present report that BALB/c Mls-1  b mice 
progressively  modify their  T  cell repertoire  in  an  Mls-1 a 
fashion,  although  the  expression  of  Mls-lqike  antigen 
cannot  be demonstrated. 
In a group of mice tested between 27 and 43 wk of age, 
50% of them had deleted both T  cells using the Vfl6 and 
the Vfl8.1 chains of the TCR,  like their BALB.D2 Mls-1 ' 
congenic partners. Deletion affects the mature T cells in the 
thymus and the peripheral lymphoid organs,  spleen, and lymph 
nodes. In the thymus, deletion occurs at the level of imma- 
ture Jlld + thymocytes, within the small subset of cells ex- 
pressing a high level of Vfl6. They likely correlate with the 
generative compartment  of CD4 + CD8 + thymocytes which 
have already been shown to be the  target  for  self-reactive 
thymocyte deletion (4,  27, 28).  These results suggest that 
the process of donal deletion in the BALB/c-MLS-1  b mice 
affects the thymus at the stage of the developing thymocytes 
as previously shown for Mls-P mice (4, 28). Within the ma- 
ture  T  cell  compartment,  CD4+CD8 -  cells  were  more 
affected by this deletion than were CD4-CD8 + cells. This 
has already been shown for the deletion of Vfl3 + T  cells in 
Mls-2  ' mice (29),  although Vfl6 deletion in Mls-1 ' mice was 
shown to equally affect  both CD4 + and CD8 + (1,  4).  In 
the case of Vfl6 deletion in BALB/c-MIs-1  b mice, it is pos- 
sible that  a small percentage of CD4 +CD8 + Vfl6hig  h cells 
that  escape deletion  is  able to  give rise to mainly  CD4- 
CD8 + Vfl6 §  cells  able to migrate  to the periphery. 
Deletion of Vfl6 + T  cells is a progressive, age-dependent 
phenomenon.  This is also the case for the deletion of Vfl6 + 
T  cells in Mls-1 ￿9 mice, where tolerance is not complete be- 
fore several days after birth (30), for Vf114 deletion in milk- 
transmitted infection by MMTV (9), and for mice transgenic 
for this virus (11). In the case of BALB/c mice, the percentage 
of Vfl6 §  cells in the thymus is very high during  the two 
first  weeks of life (between  16 and  19%  of CD4§  - 
cells).  This percentage is considerably higher than what has 
been published elsewhere for young BALB/c (30). Enhance- 
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ulation of Vfl6 + cells previous to clonal deletion, as has al- 
ready been shown for the induction  of tolerance to Mls-1 ~ 
(31). This hypothesis is currently under investigation.  In young 
adults (5-8-wk-old), the percentage of V36 + cells is lower, 
however with a wide range in the thymus, lymph nodes (Fig. 
1), and spleen (data not shown). During a transitional period 
(14-19 wk), there appears to be a crisis  in the thymus, and 
virtually all thymuses seem to be involved in the process of 
reducing V36 expression. However, during the same transi- 
tional period, lymph nodes segregate dearly into two groups 
which were or were not deleted. This may indicate that the 
antigen involved in the clonal deletion is located primarily 
in all the thymuses, where it may affect developing thymo- 
cytes in different proportions  in individual  mice.  The fact 
that some of the mice appear to further recover normal levels 
of V36 + T cells in their thymuses, and have normal expres- 
sion of V36 in their lymph nodes and spleen, is unique from 
what has been previously described for all clonal deletion where 
all  mice  were  modified.  Among  seven  different  Mls-1 b 
strains tested, BALB/c (males and females) was the only one 
to delete V36 and V38.1 with aging.  In particular,  B10.D2 
with the same H-2 haplotype and I-E expression did not show 
the same deleting pattern, which excludes the possibility that 
the absence of deletion in the other aging mice was linked 
to nonpermissive MHC, as was described for the MHC con- 
trol of Mls-1 ~ tolerance (4). 
The nature of the antigen involved in this process is not 
known. As the phenotype of aging BALB/c mice was Mls- 
l~-like, we tested whether an Mls-l~-like  antigen was detect- 
able in V36-deleted mice. Mixed lymphocyte cultures were 
done  between  irradiated  spleen  cells  from  V36 +  T  cell- 
deleted BALB/c and CD4+CD8 -  thymocytes from young 
BALB/c with normal VB6 expression, or the Mls-l~-specific 
T cell line. Although these cells respond appropriately to Mls- 
I a antigen on BALB.D2-Mls-1 ~ spleen cells,  Mls-l~-like an- 
tigen could not be detected on the cells from V36-deleted 
BALB/c mice. The hypothesis that Mls-l~-like antigen could 
not be detected because BALB/c cells were not  permissive 
for  the  presentation  of  Mls-1 ~  antigen  is  unlikely,  as 
BALB.D2 (which properly present Mls-1 ~) and BALB/c mice 
are maintained  in strict congenic state and were H-2 iden- 
tical  (13).  Furthermore,  the ability of an antigen  to induce 
clonal deletion in vivo and to stimulate the specific T  cells 
in vitro is not always concurrent.  This is true for the prod- 
ucts of Mls-3  ~, Mls-1 ~, or I-E which induce deletion of V33, 
5, 9, or 11 positive T ceils in vivo, but are not able to induce 
their stimulation in vitro (5, 29, 32). As shown by Pitcher 
et al. (33) in transgenic mice, the quality of the antigen and 
a low-avidity receptor interaction  may account for these results. 
This may also be the case for the new Mls-l~-like  antigen 
in BALB/c mice which can induce clonal deletion in vivo, 
but not  stimulated V36 + T  cells  in vitro.  In  that  case,  it 
is difficult to explain why the injection of BALB/c VB6-deleted 
spleen cells into newborn BALB/c could not induce V36 donal 
deletion as does the injection of congenic BALB.D2 Mls-1 ~ 
spleen cells. Maybe the tolerogenic antigen is not (or is no 
more)  in  the  spleen of V/36-deleted BALB/c. 
However, it is clear from our grafting experiments that 
the tolerogenic antigen is still present in the old mice, which 
have deleted V36 + and V38.1 + T  cells. This is depicted in 
Table  5 which shows that  newborn  thymuses grafted into 
old mice behave like the recipient's thymus.  After 5 wk in 
situ,  CD4+CD8 -  VB6 +  cells  of the  grafted  thymus  are 
deleted when they are deleted in the recipient's thymus. As 
recipient  and  grafted  thymuses  are  both  seeded  by  the 
recipient's bone marrow, we tried to induce VB6 clonal dele- 
tion in newborn mice by injecting bone marrow cells. Clonal 
deletion could be obtained with BALB.D2 but not with Vf6- 
deleted BALB/c bone marrow cells (Table 4). One possibility 
is that clonal deletion may be induced in newborn grafted 
thymuses by activated T cells migrating from the recipients 
into the grafts. These T  cells have been shown by Agus et 
al.  (34)  to be the only ones to efficiently migrate back to 
the thymus, and are proposed to participate in the self-tolerance 
induction process. This may be possible if cells activated by 
the antigen are still present in old BALB/c. The antigen may 
also be expressed by thymic stromal cells or B cells. This study 
is now in progress. 
It is therefore clear  that the antigen involved is not iden- 
tical to Mls-1  ~ which is the product of the Mtv-7 provirus 
in Mls-1 ~ mice (6), and which is mainly presented by CD4- 
CD8-  spleen cells  (22).  Indeed we have  verified that  the 
Mtv-7 provirus easily identified as a 2.3-kb PvulI fragment 
in DBA/2 and BALB.D2-Mls-1  ~ mice DNA was not present 
in the genome of this BALB/c colony. The epidemiology of 
the phenomenon in aging BALB/c, which is progressive, seems 
more or less to affect all thymuses at "~ 14-19 wk of age, after 
which part of them recover, which is compatible with an 
infectious process. This may be the replication of an endoge- 
nous virus, the transmission of an exogenous one, as shown 
for  milk-transmitted  MMTV  in  C3H  mice  which  delete 
V314 + T  cells (9), or be linked to a nonviral type of infec- 
tion  and  antigen(s)  (V314  is  not  deleted  in  our  BALB/c 
colony). Genetic studies that  are now in progress and the 
use of foster mothers to check for milk-transmitted virus will 
help to answer these questions. Two other colonies of BALB/c 
mice have also been tested: one colony in Belgium tested by 
A. M. Rongy in the laboratory of J. Boniver in Liege, and 
one colony in Australia, tested by C. Tucek in the laboratory 
of R. Boyd. The fact that mice from these two colonies do 
not delete V/36 while aging strengthened the exogenous in- 
fectious origin  of this clonal deletion. 
This new VB-deleting factor in BALB/c mice of this par- 
ticular colony behaves like the product of other retroviruses 
or bacterial  superantigens.  It  suggests that  clonal deletion 
is a more common phenomenon than expected, which may 
occur each time a new retrovirus or other superantigen con- 
fronts the immune system. It may benefit the mice that in 
this  manner  escape  autoreactivity  or  the  expansion  of 
retroviruses, by limiting  their number and possible activa- 
tion of their target cells by deletion and/or anergy. Conversely, 
it  may be detrimental,  by limiting  recognition  of certain 
specific  and  pathogenic  antigens,  or lead  to  acquired  im- 
munodeficiency when the deletion  is polyclonal. 
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